Skip to main content

16-06-2020 | Haematology | Video

EHA25 | Optimal approach for high-dose methotrexate CNS prophylaxis in DLBCL assessed

Matthew Wilson outlines the key results of their study evaluating the optimal timing for administering high-dose methotrexate to reduce the risk of central nervous system relapse in patients with diffuse large B-cell lymphoma (6:13).

Funding for independent interviews at EHA25 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.